Moreover, the most promising affibody variants were comparable to a clinically evaluated HER3‐targeting antibody in terms of tumour growth inhibition and prolonged survival of mice harbouring HER3‐expressing pancreatic cancer xenografts (Dahlsson Leitao et al., 2020). This evidence concerns the gene ERBB3 and pancreatic neoplasm.